You are here

Our science / Clinical Trials / Find a Trial / NCT00752232

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Back to Search Print Save as PDF Bookmark Trial

NCT00752232

Last updated on March 14, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Suwa Red Cross Hospital
Suwa, Nagano, 392-8510 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of mild to moderate Alzheimer's Disease

- Mini Mental Status Exam (MMSE) of 16-26

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Significant Neurological Disease

- Major Psychiatric Disorder

- Clinically significant systemic illness

NCT00752232
Pfizer
Completed
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Alzheimer Disease
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
NCT00277810
All Genders
50+
Years
Multiple Sites
Alzheimer Disease
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
NCT00996918
All Genders
51+
Years
Multiple Sites
Alzheimer Disease, Healthy Subjects
Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
NCT00795730
All Genders
18+
Years
Glendale, California
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
NCT00397891
All Genders
50+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now